Exact Mass: 337.146

Exact Mass Matches: 337.146

Found 110 metabolites which its exact mass value is equals to given mass value 337.146, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Linezolid

N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide

C16H20FN3O4 (337.1438)


Linezolid is only found in individuals that have used or taken this drug. It is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). Linezolid is a synthetic antibacterial agent of the oxazolidinone class of antibiotics. It has in vitro activity against aerobic Gram positive bacteria, certain Gram negative bacteria and anaerobic microorganisms. It selectively inhibits bacterial protein synthesis through binding to sites on the bacterial ribosome and prevents the formation of a functional 70S-initiation complex. Specifically, linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process. The results of time-kill studies have shown linezolid to be bacteriostatic against enterococci and staphylococci. For streptococci, linezolid was found to be bactericidal for the majority of strains. Linezolid is also a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D000890 - Anti-Infective Agents > D023303 - Oxazolidinones C254 - Anti-Infective Agent > C258 - Antibiotic

   

Streptobiosamine

Streptobiosamine

C13H23NO9 (337.1373)


An amino disaccharide that is a 2-deoxy-2-(methylamino)-alpha-L-glucopyranose ring joined to a L-lyxose with a formyl substituent at position 3.

   

Talampanel

Talampanel

C19H19N3O3 (337.1426)


C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant Same as: D02696 Talampanel (LY300164) is an orally and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor antagonis with anti-seizure activity[1]. Talampanel (IVAX) has neuroprotective effects in rodent stroke models[2]. Talampanel attenuates caspase-3 dependent apoptosis in mouse brain[2].

   

4-O-alpha-D-Galactopyranosylcalystegine B2

4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-8-azabicyclo[3.2.1]octane-1,2,3-triol

C13H23NO9 (337.1373)


4-O-alpha-D-Galactopyranosylcalystegine B2 is found in fruits. 4-O-alpha-D-Galactopyranosylcalystegine B2 is an alkaloid from the fruit of Morus alba (white mulberry). Alkaloid from the fruit of Morus alba (white mulberry). 4-O-alpha-D-Galactopyranosylcalystegine B2 is found in fruits.

   

6-oxo-famciclovir

2-[(acetyloxy)methyl]-4-(6-hydroxy-2-imino-3,9-dihydro-2H-purin-9-yl)butyl acetate

C14H19N5O5 (337.1386)


6-oxo-famciclovir is a metabolite of famciclovir. Famciclovir is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections, most commonly for herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability. Famciclovir is marketed under the trade name Famvir. On August 24, 2007, the United States Food and Drug Administration approved the first generic version of famciclovir. (Wikipedia)

   

1-(4-Aminophenyl)-3-acetyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine

1-[10-(4-aminophenyl)-13-methyl-4,6-dioxa-11,12-diazatricyclo[7.5.0.0^{3,7}]tetradeca-1,3(7),8,10-tetraen-12-yl]ethan-1-one

C19H19N3O3 (337.1426)


   

N(6)-Monobutyryladenosine

N-{9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-6-yl}butanamide

C14H19N5O5 (337.1386)


   

Ractopamine hydrochloride

4-Hydroxy-alpha-(((3-(4-hydroxyphenyl)-1-methylpropyl)amino)methyl)benzenemethanol

C18H24ClNO3 (337.1445)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists Leanness enhancer for pigs. Approved for use in the USA

   

Voxelotor

2-hydroxy-6-({2-[1-(propan-2-yl)-1H-pyrazol-5-yl]pyridin-3-yl}methoxy)benzaldehyde

C19H19N3O3 (337.1426)


   
   

3alpha-(3,4,5-Trimethoxybenzoyloxy)nortropan-6beta-ol

3alpha-(3,4,5-Trimethoxybenzoyloxy)nortropan-6beta-ol

C17H23NO6 (337.1525)


   
   
   
   

2-O-Methyl-b-D-N-acetylneuraminic acid methyl ester

2-O-Methyl-b-D-N-acetylneuraminic acid methyl ester

C13H23NO9 (337.1373)


   

SCHEMBL4265170

SCHEMBL4265170

C13H23NO9 (337.1373)


   

(Xi)-beta-D-Glucopyranosyloxy-(4-isopropyl-phenyl)-acetonitril|(Xi)-beta-D-glucopyranosyloxy-(4-isopropyl-phenyl)-acetonitrile

(Xi)-beta-D-Glucopyranosyloxy-(4-isopropyl-phenyl)-acetonitril|(Xi)-beta-D-glucopyranosyloxy-(4-isopropyl-phenyl)-acetonitrile

C17H23NO6 (337.1525)


   

4-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]-5-oxo-5-phenylmethoxypentanoic acid

4-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]-5-oxo-5-phenylmethoxypentanoic acid

C17H23NO6 (337.1525)


   

1,4,9-trihydroxynonene mercapturic acid

1,4,9-trihydroxynonene mercapturic acid

C14H27NO6S (337.1559)


   

Linezolid

Linezolid (Zyvox)

C16H20FN3O4 (337.1438)


J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D000890 - Anti-Infective Agents > D023303 - Oxazolidinones C254 - Anti-Infective Agent > C258 - Antibiotic CONFIDENCE standard compound; EAWAG_UCHEM_ID 3291

   

N2-Isobutyryl-2-deoxyguanosine

N2-Isobutyryl-2-deoxyguanosine

C14H19N5O5 (337.1386)


relative retention time with respect to 9-anthracene Carboxylic Acid is 0.589 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.591 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.583 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.587

   
   
   

N2-Isobutyl-deoxyguanosine

N2-Isobutyl-deoxyguanosine

C14H19N5O5 (337.1386)


   

N2-(S)-Propano-deoxyguanosine

N2-(S)-Propano-deoxyguanosine

C14H19N5O5 (337.1386)


   

N2-(R)-Propano-deoxyguanosine

N2-(R)-Propano-deoxyguanosine

C14H19N5O5 (337.1386)


   

Desmethylpirenzepine

Desmethylpirenzepine

C18H19N5O2 (337.1539)


   

Zolpidem Metabolite I

Zolpidem Metabolite I

C19H19N3O3 (337.1426)


   

Zolpidem Metabolite II

Zolpidem Metabolite II

C19H19N3O3 (337.1426)


   

4-O-a-D-Galactopyranosylcalystegine b2

4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-8-azabicyclo[3.2.1]octane-1,2,3-triol

C13H23NO9 (337.1373)


   
   
   

Boc-D-glutamic acid α-benzylester

Boc-D-glutamic acid α-benzylester

C17H23NO6 (337.1525)


   

Boc-β-homo-Asp(OBzl)-OH

Boc-β-homo-Asp(OBzl)-OH

C17H23NO6 (337.1525)


   

N-Cbz-L-Glutamic acid 5-tert-butyl ester

N-Cbz-L-Glutamic acid 5-tert-butyl ester

C17H23NO6 (337.1525)


   

Boc-L-Glutamic acid 5-benzylester

Boc-L-Glutamic acid 5-benzylester

C17H23NO6 (337.1525)


   

Boc-D-Glutamic acid 5-benzylester

Boc-D-Glutamic acid 5-benzylester

C17H23NO6 (337.1525)


   

z-β-glu(otbu)-oh

z-β-glu(otbu)-oh

C17H23NO6 (337.1525)


   

N-(2,5,8,11,14-pentaoxabicyclo[13.4.0]nonadeca-1(15),16,18-trien-17-yl)prop-2-enamide

N-(2,5,8,11,14-pentaoxabicyclo[13.4.0]nonadeca-1(15),16,18-trien-17-yl)prop-2-enamide

C17H23NO6 (337.1525)


   

Z-D-Glu(OtBu)-OH

Z-D-Glu(OtBu)-OH

C17H23NO6 (337.1525)


   
   

1-((4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)SULFONYL)PYRROLIDINE

1-((4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)SULFONYL)PYRROLIDINE

C16H24BNO4S (337.1519)


   

2-Naphthalenol,1-[phenyl[(phenylmethylene)amino]methyl]-

2-Naphthalenol,1-[phenyl[(phenylmethylene)amino]methyl]-

C24H19NO (337.1467)


   

1-O-tert-butyl 4-O-methyl 2-(phenylmethoxycarbonylamino)butanedioate

1-O-tert-butyl 4-O-methyl 2-(phenylmethoxycarbonylamino)butanedioate

C17H23NO6 (337.1525)


   

Dobutamine hydrochloride

Dobutamine hydrochloride

C18H24ClNO3 (337.1445)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents Dobutamine hydrochloride is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine hydrochloride is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine hydrochloride can increase cardiac output and correct hypoperfusion[1][2][3][4].

   
   
   

Z-Asp(OtBu)-Ome

Z-Asp(OtBu)-Ome

C17H23NO6 (337.1525)


   

Boc-L-glutamic acid 1-benzyl ester

Boc-L-glutamic acid 1-benzyl ester

C17H23NO6 (337.1525)


   

(R)-3-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-(hydroxyMethyl)oxazolidin-2-one

(R)-3-(3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-5-(hydroxyMethyl)oxazolidin-2-one

C16H21BFNO5 (337.1497)


   

AntioxidantIPPSI

AntioxidantIPPSI

C18H19N5S (337.1361)


   

Voxelotor

Voxelotor

C19H19N3O3 (337.1426)


C78275 - Agent Affecting Blood or Body Fluid B - Blood and blood forming organs D006401 - Hematologic Agents

   

Clenpenterol-D11 hydrochloride

Clenpenterol-D11 hydrochloride

C13H10D11Cl3N2O (337.141)


   
   

Isoxsuprine hydrochloride

Isoxsuprine hydrochloride

C18H24ClNO3 (337.1445)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Isoxsuprine hydrochloride is a beta-adrenergic receptor agonist with Kis of 13.65 μΜ and 3.48 μΜ for myometrial and placcntal beta-adrenergic receptor, respectively. Isoxsuprine hydrochloride is also a NMDA receptor antagonist.

   

Tecadenoson

Tecadenoson

C14H19N5O5 (337.1386)


D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent Tecadenoson (CVT-510) is a selective A1 adenosine receptor agonist. Tecadenoson (CVT-510) is a selective A1 adenosine receptor agonist.

   

6-[(Z)-2-(2,5-dimethoxyphenyl)ethenyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine

6-[(Z)-2-(2,5-dimethoxyphenyl)ethenyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine

C18H19N5O2 (337.1539)


   

6-oxo-famciclovir

6-oxo-famciclovir

C14H19N5O5 (337.1386)


   

(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-(4-chlorophenoxy)butanoate

(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-(4-chlorophenoxy)butanoate

C18H24ClNO3 (337.1445)


   

[4-(Benzenesulfonyl)-1-piperazinyl]-(1-piperidinyl)methanone

[4-(Benzenesulfonyl)-1-piperazinyl]-(1-piperidinyl)methanone

C16H23N3O3S (337.146)


   

N-[(1,2-dimethyl-5-indolyl)methyl]-2-(4-nitrophenyl)acetamide

N-[(1,2-dimethyl-5-indolyl)methyl]-2-(4-nitrophenyl)acetamide

C19H19N3O3 (337.1426)


   

3-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-N-(3-methylphenyl)propanamide

3-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-N-(3-methylphenyl)propanamide

C19H19N3O3 (337.1426)


   

N-[(1,2-dimethyl-5-indolyl)methyl]-2-methyl-3-nitrobenzamide

N-[(1,2-dimethyl-5-indolyl)methyl]-2-methyl-3-nitrobenzamide

C19H19N3O3 (337.1426)


   
   

Cyclic 1,N(2)-propanodeoxyguanosine

Cyclic 1,N(2)-propanodeoxyguanosine

C14H19N5O5 (337.1386)


   

(2S)-N-[(3Z)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxoimidazolidin-1-YL)phenyl]propanamide

(2S)-N-[(3Z)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxoimidazolidin-1-YL)phenyl]propanamide

C18H19N5O2 (337.1539)


   

Ractopamine Hydrochloride

Ractopamine Hydrochloride

C18H24ClNO3 (337.1445)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists

   

3-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-N-(3-methylpyridin-2-yl)benzamide

3-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-N-(3-methylpyridin-2-yl)benzamide

C19H19N3O3 (337.1426)


   

(3Z,5S)-3-(1-oxidoethylidene)-5-{[4-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}pyrrolidine-2,4-dione(1-)

(3Z,5S)-3-(1-oxidoethylidene)-5-{[4-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}pyrrolidine-2,4-dione(1-)

C20H21N2O3- (337.1552)


   

5-amino-1-[(3-methoxyphenyl)methyl]-N-(4-methylphenyl)-4-triazolecarboxamide

5-amino-1-[(3-methoxyphenyl)methyl]-N-(4-methylphenyl)-4-triazolecarboxamide

C18H19N5O2 (337.1539)


   

4-tert-butyl-N-(1,4-dioxo-2,3-dihydrophthalazin-5-yl)benzamide

4-tert-butyl-N-(1,4-dioxo-2,3-dihydrophthalazin-5-yl)benzamide

C19H19N3O3 (337.1426)


   

2-hydroxy-4-oxo-1-propyl-N-(pyridin-4-ylmethyl)quinoline-3-carboxamide

2-hydroxy-4-oxo-1-propyl-N-(pyridin-4-ylmethyl)quinoline-3-carboxamide

C19H19N3O3 (337.1426)


   

2-amino-4-(2-ethoxyphenyl)-6,7-dimethyl-5-oxo-4H-pyrano[3,2-c]pyridine-3-carbonitrile

2-amino-4-(2-ethoxyphenyl)-6,7-dimethyl-5-oxo-4H-pyrano[3,2-c]pyridine-3-carbonitrile

C19H19N3O3 (337.1426)


   

N-(2-butan-2-ylphenyl)-7-nitro-1H-indole-2-carboxamide

N-(2-butan-2-ylphenyl)-7-nitro-1H-indole-2-carboxamide

C19H19N3O3 (337.1426)


   

2-[[2-(5,6-Dimethyl-1-benzimidazolyl)-1-oxoethyl]amino]benzoic acid methyl ester

2-[[2-(5,6-Dimethyl-1-benzimidazolyl)-1-oxoethyl]amino]benzoic acid methyl ester

C19H19N3O3 (337.1426)


   

N-(2-methoxyethyl)-3-methyl-5H-indazolo[2,3-a][3,1]benzoxazine-9-carboxamide

N-(2-methoxyethyl)-3-methyl-5H-indazolo[2,3-a][3,1]benzoxazine-9-carboxamide

C19H19N3O3 (337.1426)


   

[3-[3-(5-Methyl-2-furanyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-phenylmethanone

[3-[3-(5-Methyl-2-furanyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]-phenylmethanone

C19H19N3O3 (337.1426)


   

N-[(2S)-1-hydroxypropan-2-yl]-3-methyl-5H-indazolo[2,3-a][3,1]benzoxazine-9-carboxamide

N-[(2S)-1-hydroxypropan-2-yl]-3-methyl-5H-indazolo[2,3-a][3,1]benzoxazine-9-carboxamide

C19H19N3O3 (337.1426)


   

(1Z)-1-[(5S)-5-{[4-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}-2,4-dioxopyrrolidin-3-ylidene]ethanolate

(1Z)-1-[(5S)-5-{[4-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}-2,4-dioxopyrrolidin-3-ylidene]ethanolate

C20H21N2O3- (337.1552)


   

ethyl N-acetylneuraminate

ethyl N-acetylneuraminate

C13H23NO9 (337.1373)


   

N-[2-(3,4-dihydroxyphenyl)ethyl]-4-(4-hydroxyphenyl)butan-2-aminium chloride

N-[2-(3,4-dihydroxyphenyl)ethyl]-4-(4-hydroxyphenyl)butan-2-aminium chloride

C18H24ClNO3 (337.1445)


   

(2R,3R,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile

(2R,3R,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile

C19H19N3O3 (337.1426)


   

(2S,3S,4R)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenyl-1-azetidinecarboxamide

(2S,3S,4R)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenyl-1-azetidinecarboxamide

C19H19N3O3 (337.1426)


   

(2R,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile

(2R,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile

C19H19N3O3 (337.1426)


   

(2R,3R,4S)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenylazetidine-1-carboxamide

(2R,3R,4S)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenylazetidine-1-carboxamide

C19H19N3O3 (337.1426)


   

(2R,3R,4R)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenyl-1-azetidinecarboxamide

(2R,3R,4R)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenyl-1-azetidinecarboxamide

C19H19N3O3 (337.1426)


   

(2R,3S,4R)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenylazetidine-1-carboxamide

(2R,3S,4R)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenylazetidine-1-carboxamide

C19H19N3O3 (337.1426)


   

(2S,3R,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile

(2S,3R,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile

C19H19N3O3 (337.1426)


   

(2S,3S,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile

(2S,3S,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile

C19H19N3O3 (337.1426)


   

(2R,3S,4S)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenyl-1-azetidinecarboxamide

(2R,3S,4S)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenyl-1-azetidinecarboxamide

C19H19N3O3 (337.1426)


   

(2S,3S,4S)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenyl-1-azetidinecarboxamide

(2S,3S,4S)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenyl-1-azetidinecarboxamide

C19H19N3O3 (337.1426)


   

(2R,3S,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile

(2R,3S,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile

C19H19N3O3 (337.1426)


   

(2S,3R,4R)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenyl-1-azetidinecarboxamide

(2S,3R,4R)-2-cyano-4-(hydroxymethyl)-N-(2-methoxyphenyl)-3-phenyl-1-azetidinecarboxamide

C19H19N3O3 (337.1426)


   

N-hydroxy-N-[(E)-[(2S,3S,4S,5S)-2,3,4,5,6-pentahydroxyhexylidene]amino]hexanediamide

N-hydroxy-N-[(E)-[(2S,3S,4S,5S)-2,3,4,5,6-pentahydroxyhexylidene]amino]hexanediamide

C12H23N3O8 (337.1485)


   

N-hydroxy-N-[(E)-[(2R,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexylidene]amino]hexanediamide

N-hydroxy-N-[(E)-[(2R,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexylidene]amino]hexanediamide

C12H23N3O8 (337.1485)


   

Nonanal O-[(pentafluorophenyl)methyl]oxime

Nonanal O-[(pentafluorophenyl)methyl]oxime

C16H20F5NO (337.1465)


   

1-Acetoxy-3-(N-acetyl-2-acetoxyethylamino)-5-methoxy-2,6-dimethylbenzene

1-Acetoxy-3-(N-acetyl-2-acetoxyethylamino)-5-methoxy-2,6-dimethylbenzene

C17H23NO6 (337.1525)


   

N-Trimethylsilylphenylacetylglycine trimethylsilyl ester

N-Trimethylsilylphenylacetylglycine trimethylsilyl ester

C16H27NO3Si2 (337.1529)


   

4-O-alpha-D-Galactopyranosylcalystegine B2

4-O-alpha-D-Galactopyranosylcalystegine B2

C13H23NO9 (337.1373)


   

N-[[(5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide

N-[[(5S)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide

C16H20FN3O4 (337.1438)


   

(3Z,5S)-3-(1-oxidoethylidene)-5-{[4-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}pyrrolidine-2,4-dione(1-)

(3Z,5S)-3-(1-oxidoethylidene)-5-{[4-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}pyrrolidine-2,4-dione(1-)

C20H21N2O3 (337.1552)


Conjugate base of (3Z,5S)-3-(1-hydroxyethylidene)-5-{[4-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}pyrrolidine-2,4-dione arising from deprotonation of the enolic hydroxy group; major species at pH 7.3.

   

ISAM-140

ISAM-140

C19H19N3O3 (337.1426)


ISAM-140 (22b) is a potent and highly selective A2B adenosine receptor antagonist with a Ki of 3.49 nM[1].

   

1-[(1s,2r)-1-amino-2-{[(1r,2s)-2-amino-1-hydroxy-2-(4-oxopyridin-1-yl)ethyl](hydroxy)amino}-2-hydroxyethyl]pyridin-4-one

1-[(1s,2r)-1-amino-2-{[(1r,2s)-2-amino-1-hydroxy-2-(4-oxopyridin-1-yl)ethyl](hydroxy)amino}-2-hydroxyethyl]pyridin-4-one

C14H19N5O5 (337.1386)


   

(1r,2s,3r,5s,6r)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-8-azabicyclo[3.2.1]octane-1,2,6-triol

(1r,2s,3r,5s,6r)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-8-azabicyclo[3.2.1]octane-1,2,6-triol

C13H23NO9 (337.1373)


   

4-ethylidene-7-hydroxy-7-methyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,6,8-trione

4-ethylidene-7-hydroxy-7-methyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecane-3,6,8-trione

C17H23NO6 (337.1525)


   

3-[(2z)-4-{4-[(acetyloxy)methyl]-4-hydroxycyclohexyl}-5-oxofuran-2-ylidene]-2-methylpropanimidic acid

3-[(2z)-4-{4-[(acetyloxy)methyl]-4-hydroxycyclohexyl}-5-oxofuran-2-ylidene]-2-methylpropanimidic acid

C17H23NO6 (337.1525)


   

1-(1-amino-2-{[2-amino-1-hydroxy-2-(4-oxopyridin-1-yl)ethyl](hydroxy)amino}-2-hydroxyethyl)pyridin-4-one

1-(1-amino-2-{[2-amino-1-hydroxy-2-(4-oxopyridin-1-yl)ethyl](hydroxy)amino}-2-hydroxyethyl)pyridin-4-one

C14H19N5O5 (337.1386)


   

3-(4-{4-[(acetyloxy)methyl]-4-hydroxycyclohexyl}-5-oxofuran-2-ylidene)-2-methylpropanimidic acid

3-(4-{4-[(acetyloxy)methyl]-4-hydroxycyclohexyl}-5-oxofuran-2-ylidene)-2-methylpropanimidic acid

C17H23NO6 (337.1525)


   

3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-8-azabicyclo[3.2.1]octane-1,2,6-triol

3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-8-azabicyclo[3.2.1]octane-1,2,6-triol

C13H23NO9 (337.1373)